Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa
Research article published in Journal of medicinal chemistry (2022)
Abstract
Factor XIIa (FXIIa) is a promising target for developing new drugs that prevent thrombosis without causing bleeding complications. A native cyclotide (MCoTI-II) is gaining interest for engineering FXIIa-targeted anticoagulants as this peptide inhibits FXIIa but not other coagulation proteases. Here, we engineered the native biosynthetic cyclization loop of MCoTI-II (loop 6) to generate improved FXIIa inhibitors. Decreasing the loop length led to gains in potency up to 7.7-fold, with the most potent variant having five residues in loop 6 (Ki = 25 nM). We subsequently examined sequence changes within loop 6 and an adjacent loop, with substitutions at P4 and P2' producing a potent FXIIa inhibitor (Ki = 2 nM) that displayed more than 700-fold selectivity, was stable in human serum, and blocked the intrinsic coagulation pathway in human plasma. These findings demonstrate that engineering the biosynthetic cyclization loop can generate improved cyclotide variants, expanding their potential for drug discovery.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed clinical and outcomes research relevant to anticoagulation, leech therapy, and microsurgical flap management. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This protein-engineering study reshaped the biosynthetic cyclization loop (loop 6) of the plant-derived cyclotide MCoTI-II to build more potent, highly selective inhibitors of coagulation Factor XIIa, reporting a top variant with a Ki of 2 nM, more than 700-fold selectivity, stability in human serum, and the ability to block the intrinsic coagulation pathway in human plasma. For hirudotherapy and the leech-secretome drug-discovery story, it is a useful parallel: it shows how nature-derived peptide scaffolds can be tuned into precise, single-target anticoagulants aimed at preventing thrombosis without the bleeding seen with broad agents like heparin — the same design logic that has driven interest in leech-salivary proteins (hirudin and related molecules) as templates for modern antithrombotics. The honest caveat is that this is preclinical, in-vitro work on an engineered plant cyclotide, not a leech molecule and not a clinical trial; the potency and selectivity are biochemical findings in serum and plasma assays, with no human dosing, efficacy, or safety established.
Citation
Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa.
Tian et al. · Journal of medicinal chemistry, 2022
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026